FcR Binding Potency Assay for Antibody Batch Consistency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current assays for determining the potency of antibodies that rely on Fc receptor binding are cumbersome and variable, particularly when assessing batch consistency and stability, especially for pharmaceutical compositions where Fc-mediated activities are critical, such as Zanolimumab and Zalutumumab, due to factors like cell culture variations and donor immune status.
Innovation Solution
A method is developed to determine the potency of drug products by measuring the binding of FcR binding peptides to Fc receptors, using techniques like ELISA, AlphaScreen, or BIAcore, which allows for a direct and sensitive assessment of FcR binding, reducing the need for complex bioassays and providing a robust, high-throughput analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional bioassays are used to determine antibody potency, then the assay can detect Fc-mediated activities, but the assay becomes cumbersome and highly variable
Solution Approach 1:
The patent extracts the Fc receptor binding function from complex cell-based bioassays and isolates it into a simplified direct binding assay. By using purified Fc receptors immobilized on solid support, the assay removes confounding variables from cell culture and donor immune status, achieving consistent results without the complexity of traditional bioassays
Solution Approach 2:
The patent introduces purified Fc receptors as an intermediary component between the antibody and the detection system. This intermediary allows direct measurement of Fc-mediated potency without requiring complex cell-based systems, thereby simplifying the assay while maintaining reliability
2Measurement precision
If cell-based assays are used to assess Fc-mediated activities, then the assay can measure physiological activity, but the assay shows high variability due to cell culture and donor factors
Solution Approach 1:
The patent uses recombinant Fc receptors that are produced in a controlled manner and immobilized on solid support. These self-contained receptor preparations eliminate the need for donor-derived cells, removing variability from cell culture conditions and donor immune status while maintaining the ability to measure Fc-mediated potency accurately
Solution Approach 2:
The patent creates a simplified copy of the physiological Fc receptor-antibody interaction by immobilizing purified Fc receptors on solid support. This copy captures the essential binding event without requiring the complex cellular environment, achieving precise and consistent potency measurements across batches
3Productivity
If complex bioassays are used for potency determination, then the assay can assess mechanism of action, but the assay is not suitable for high-throughput analysis
Solution Approach 1:
The patent replaces the mechanical complexity of cell-based assays with a simplified solid-phase binding assay. By immobilizing Fc receptors on plates or beads, the assay eliminates the need for complex cell handling, culture, and maintenance steps, enabling high-throughput analysis while maintaining the ability to assess Fc-mediated mechanism of action
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a fast, efficient, and sensitive means to assess the potency of antibodies, ensuring batch consistency and stability by directly measuring FcR binding, thereby supporting regulatory approval processes and ensuring therapeutic efficacy.
Implementation Method 1
wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor
Data Source
AI summary
The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor.